Eosinophilic Esophagitis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
Eosinophilic esophagitis (EoE) is a chronic, allergic inflammatory disease of the esophagus, characterized by an accumulation of eosinophils. It can cause difficulty with swallowing food and has the potential to cause dangerous food impaction. Generically available treatments, such as proton pump inhibitors (PPIs) and topical steroids, are the mainstays of clinical management of EoE. However, novel therapies are starting to come to market from the EoE pipeline, highlighted by the FDA approval of Sanofi / Regeneron’s Dupixent (dupilumab) for EoE in 2022. Several additional therapies are in the pipeline for EoE, including Tezspire (AstraZeneca / Amgen), lirentelimab (Allakos), APT-1011 (Ellodi), and CC-93538 (Celgene). As the EoE treatment landscape evolves, this report offers insight from real-world claims data into prescribing trends in EoE to help developers better understand current treatment and define the market niche for emerging products.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed EoE patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed EoE patients?
- How have biologics been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of EoE patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of EoE patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Sanofi / Regeneron, AstraZeneca, Pfizer, Merck, GSK, Teva
Key drugs: PPIs (e.g., omeprazole, pantoprazole, esomeprazole), topical glucocorticoids (e.g., fluticasone propionate), oral / systemic glucocorticoids (e.g., prednisone), Dupixent (dupilumab), Tezspire (tezepelumab)
SOLUTION ENHANCEMENT
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.
Table of contents
- Eosinophilic Esophagitis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
- Treatment Algorithms CDA Eosinophilic Esophagitis US April 2023
- Treatment Algorithms CDA Eosinophilic Esophagitis 2023 Dashboard
Preeti Attri, M.Sc., Ph.D., is an associate analyst on the Infectious, Niche, and Rare Diseases team. Prior to joining Clarivate, she was a business analyst at Smart Analyst (India) Private Limited. She has experience in market assessment, competitive intelligence, primary market research, market forecasting, analogue and indication assessment, disease portfolio optimization, and database research. She received her Ph.D. in cancer epigenetics from the National Institute of Immunology in New Delhi.